Guide to EU Pharmaceutical Regulatory Law - Tapa blanda

Guide to EU Pharmaceutical Regulatory Law, which is updated annually to reflect the speed at which the rules and regulations change, provides a comprehensive and practical guide to, and analysis of, the current European Union (EU) Pharmaceutical Regulatory Regime. In the EU and its Member States, as elsewhere, the marketing of pharmaceuticals has become subject to an increasingly complex web of legislation and regulation, resulting from the intense scrutiny necessary to ensure that such essential products are not only efficacious but also safe. This useful volume lays out this system with extraordinary clarity and logic. Adopting a Europe-wide perspective on the law governing pharmaceuticals, expert authors from the law firm Bird & Bird LLP map the life cycle of a medicinal product or medical device from development to product launch and ongoing pharmacovigilance, offering comprehensive and unambiguous guidance at every stage.

What’s in this book:

Following an introductory overview focusing on the regulatory framework for pharmaceuticals in Europe – from its underlying rationales to the relevant committees and agencies – each of the fifteen incisive chapters examines a particular process or subject. Among the many topics and issues covered are the following:

• obtaining a marketing authorisation;
• stages and standards for creating a product dossier;
• clinical trials;
• how and when an abridged procedure can be used;
• criteria for conditional marketing authorisations;
• generic products and ‘essential similarity’;
• paediatric use and the requisite additional trials;
• biologicals and ‘biosimilars’;
• homeopathic and herbal medicines;
• reporting procedures;
• pharmacovigilance;
• parallel trade;
• relevant competition law and IP rights; and
• advertising.

In addition, national variation charts in many of the chapters illustrate how the regime operates in the eight major jurisdictions (Belgium, France, Germany, Italy, The Netherlands, Spain, Sweden, and the UK). Sample forms and URLs for the most important Directives are also included. A brief overview of how the proposed exit from the EU by the UK will affect the regulatory regime is also included.

How this will help you:

Starting with an overview, this book primarily deals with how pharmaceutical products are brought to market from the conduct of clinical trials through amendments to marketing authorisations and abridged (generic) applications – the routes to obtaining a marketing authorisation covering special regimes such as the paediatric system and conditional marketing authorisations. Thus, this book serves as a guide for pharmaceutical lawyers and regulatory advisers, both in-house and in private practice, who need to understand the process of bringing a medicinal product or medical device to market and the continuing rights and obligations. In addition, this book also provides guidance on how ancillary subjects such as IP law, competition law, parallel imports and the regulation of homeopathic products influence pharmaceutical regime.

Sally joined Bird & Bird in September 2006 as a Partner in the Intellectual Property Group, based in London. After studying law at Manchester University and then the College of Law, she completed her training at Herbert Smith and qualified in 1988. After a period as a solicitor at Herbert Smith, Sally spent eleven years working in-house firstly as senior legal advisor at ICI/Zeneca and latterly as Legal Director of Novartis UK, where she was responsible for all legal matters for the Novartis Group within the UK with particular responsibility for intellectual property protection, regulatory compliance and competition law compliance. She was Head of IP and Life Sciences at another international firm before joining Bird & Bird. As a transactional IP lawyer, Sally has been involved in providing advice in relation to the protection and exploitation of a full range of intellectual property rights, from design rights to patents, trade marks, copyright and confidentiality across a range of jurisdictions, both in stand alone transactions and in conjunction with her corporate colleagues as part of an acquisition, divestment or investment activity. Sally provides a full range of IP commercial advice and support to her clients, including licensing, partnering joint ventures and exploitation agreements, research, development and marketing collaborations. She also frequently advises clients on regulatory and freedom to operate matters, and manages significant due diligence matters. Sally is a regular speaker at conferences and seminars on a range of IP related subjects, particularly in relation to regulatory, licensing and exploitation matters.